ניקסואה נכנסת לפרק חדש של יצירת ערך לטווח ארוך
תחילת תהליך
המעבר למנכ"ל שבסיסו בארה"ב
מעבר לתמיכה בהאצה נוספת של השקה מסחרית של Genio בארצות הברית
מונט-סן-גיבר, בלגיה – 4 ביוני 2026, GLOBE NEWSWIRE –
Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המתמקדת בפיתוח פתרונות
חדשניים לטיפול בדום נשימה חסימתי בשינה (OSA), הודיעה היום על תחילת תהליך מעבר מנהלים במטרה להאיץ עוד יותר את ההתקדמות
המסחרית של החברה בארה"ב.
Nyxoah Enters New Chapter of Long Term Value Creation
Commencement of process to transition to a
U.S.-based CEO
Transition to support further acceleration of commercial Genio launch in the
United States
Mont-Saint-Guibert, Belgium – June 4, 2026, GLOBE NEWSWIRE:
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical
technology company focused on developing innovative solutions for Obstructive
Sleep Apnea (OSA), today announced the commencement of a leadership transition
process in order to further accelerate the Company’s U.S. commercial traction.
Following seven successful years leading
Nyxoah, Olivier Taelman, together with the Board of Directors, has decided that
this is the right moment to transition leadership to a U.S.-based Chief
Executive Officer as the Company enters its next phase of U.S.-driven growth
and value creation. The Board has formally launched a search process to appoint
a new U.S.-based CEO who will lead Nyxoah from within a critical market for the
Company’s future growth.
Mr. Taelman will remain fully engaged during
the transition period, continuing to lead the Company’s daily operations and to
support a smooth onboarding and successful transition to the future CEO.
“Leading Nyxoah over the past seven years has
been one of the most rewarding journeys of my professional career,” said Mr.
Taelman. “Together with an exceptional team, we transformed Nyxoah from an
early-stage clinical company into a global commercial medical technology
platform with FDA PMA approval, successful IPOs on Euronext Brussels and
Nasdaq, and a promising early commercial launch of Genio in the United States.”
Robert Taub, Chairman commented: “We
appreciate Olivier Taelman’s outstanding contributions. The combination of
strengthened financial resources, accelerating U.S. commercial momentum and a
U.S.-focused leadership structure will position Nyxoah well for its next phase
of growth in the rapidly expanding OSA market.”
About Nyxoah
Nyxoah is a medical technology company
focused on the development and commercialization of innovative solutions to
treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for OSA, the
world’s most common sleep disordered breathing condition that is associated
with increased mortality risk and cardiovascular comorbidities. Nyxoah is
driven by the vision that OSA patients should enjoy restful nights and feel
enabled to live their life to its fullest.
Following the successful completion of the
BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah
completed two successful IPOs: on Euronext Brussels in September 2020 and
NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study,
Nyxoah received CE mark approval for the expansion of its therapeutic
indications to Complete Concentric Collapse (CCC) patients, currently
contraindicated in competitors’ therapy. Additionally, the Company announced
positive outcomes from the DREAM IDE pivotal study and receipt of approval from
the FDA for a subset of adult patients with moderate to severe OSA with an AHI
of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in
August 2025 as prescription-only device.
תגובות
הוסף רשומת תגובה